ATE353081T1 - Verfahren zur herstellung von duloxetin und deren verwendeten zwischenprodukten - Google Patents

Verfahren zur herstellung von duloxetin und deren verwendeten zwischenprodukten

Info

Publication number
ATE353081T1
ATE353081T1 AT03767973T AT03767973T ATE353081T1 AT E353081 T1 ATE353081 T1 AT E353081T1 AT 03767973 T AT03767973 T AT 03767973T AT 03767973 T AT03767973 T AT 03767973T AT E353081 T1 ATE353081 T1 AT E353081T1
Authority
AT
Austria
Prior art keywords
duloxetine
acid addition
addition salt
intermediate products
products used
Prior art date
Application number
AT03767973T
Other languages
English (en)
Inventor
Dharmaraj R Rao
Rajendra Narayanrao Kankan
Original Assignee
Cipla Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9949985&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE353081(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cipla Ltd filed Critical Cipla Ltd
Application granted granted Critical
Publication of ATE353081T1 publication Critical patent/ATE353081T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/16Radicals substituted by singly bound hetero atoms other than halogen by oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT03767973T 2002-12-19 2003-12-10 Verfahren zur herstellung von duloxetin und deren verwendeten zwischenprodukten ATE353081T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0229583.0A GB0229583D0 (en) 2002-12-19 2002-12-19 A process for preparing duloxetine and intermediates for use therein

Publications (1)

Publication Number Publication Date
ATE353081T1 true ATE353081T1 (de) 2007-02-15

Family

ID=9949985

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03767973T ATE353081T1 (de) 2002-12-19 2003-12-10 Verfahren zur herstellung von duloxetin und deren verwendeten zwischenprodukten

Country Status (24)

Country Link
US (1) US7645890B2 (de)
EP (2) EP1587801B1 (de)
JP (1) JP5259048B2 (de)
KR (1) KR100926723B1 (de)
CN (2) CN100579975C (de)
AT (1) ATE353081T1 (de)
AU (2) AU2003292396B2 (de)
BR (1) BR0316902A (de)
CA (1) CA2510750A1 (de)
DE (1) DE60311599T2 (de)
ES (1) ES2279971T3 (de)
GB (1) GB0229583D0 (de)
HR (1) HRP20050657A2 (de)
IL (1) IL169232A (de)
IS (1) IS7915A (de)
MA (1) MA27706A1 (de)
MX (1) MXPA05006659A (de)
NZ (2) NZ540881A (de)
PL (1) PL377380A1 (de)
PT (1) PT1587801E (de)
RU (1) RU2351594C2 (de)
TN (1) TNSN05167A1 (de)
WO (1) WO2004056795A1 (de)
ZA (1) ZA200505656B (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7550605B2 (en) * 2004-08-05 2009-06-23 Sun Pharmaceutical Industries Ltd. Process for preparation of an anitdepressant compound
CZ297560B6 (cs) * 2004-10-26 2007-02-07 Zentiva, A. S. Zpusob výroby hydrochloridu (S)-N-methyl-3-(1-naftyloxy)-3-(2-thienyl)propylaminu (duloxetinu)
EP1730132A2 (de) * 2004-12-23 2006-12-13 Teva Pharmaceutical Industries Ltd Verfahren zur herstellung pharmazeutisch unbedenklicher salze von duloxetin und zwischenprodukten davon
US20060270859A1 (en) * 2005-01-27 2006-11-30 Santiago Ini Duloxetine HCl polymorphs
MX2007010931A (es) 2005-03-08 2007-10-16 Teva Pharma Formas cristalinas de (s)-(+)-n,n-dimetil-3-(1-naftaleniloxi)-3-(2 -tienil)propanamina oxalato y la preparacion ellas.
US20060270861A1 (en) * 2005-03-14 2006-11-30 Santiago Ini Process for the preparation of optically active (S)-(+)-N,N-dimethyl-3-(1-naphthalenyloxy)-3-(2-thienyl)propanamine
US8093408B2 (en) * 2005-06-21 2012-01-10 The Company Wockhardt Antidepressant oral pharmaceutical compositions
US8153824B2 (en) * 2005-06-22 2012-04-10 The Wockhardt Company Antidepressant oral liquid compositions
US7842717B2 (en) 2005-09-22 2010-11-30 Teva Pharmaceutical Industries Ltd. DNT-maleate and methods of preparation thereof
US7759500B2 (en) 2005-12-05 2010-07-20 Teva Pharmaceutical Industries Ltd. 2-(N-methyl-propanamine)-3-(2-naphthol)thiophene, an impurity of duloxetine hydrochloride
CA2634008A1 (en) * 2005-12-12 2007-10-25 Medichem, S.A. Improved synthesis and preparations of duloxetine salts
CZ299270B6 (cs) * 2006-01-04 2008-06-04 Zentiva, A. S. Zpusob výroby hydrochloridu (S)-N-methyl-3-(1-naftyloxy)-3-(2-thienyl)propylaminu
EP1976844A4 (de) * 2006-01-06 2010-11-03 Msn Lab Ltd Verbessertes verfahren für reines duloxetin-hydrochlorid
US7538232B2 (en) 2006-01-19 2009-05-26 Eli Lilly And Company Process for the asymmetric synthesis of duloxetine
CA2640212A1 (en) * 2006-02-13 2007-08-23 Teva Pharmaceutical Industries Ltd. A process for the preparation of (s)-(+)-n,n-dimethyl-3-(1-naphthalenyloxy)-3-(2-thienyl)propanamine, a duloxetine intermediate
HU228458B1 (en) * 2006-03-13 2013-03-28 Egis Gyogyszergyar Nyrt Duloxetine salts for producing pharmaceutical compositions
DE602006015617D1 (de) 2006-05-05 2010-09-02 Fidia Farmaceutici Verfahren zur Herstellung eines Zwischenprodukts für die asymmetrische Synthese von (+)Duloxetine
CN101448815A (zh) * 2006-05-23 2009-06-03 特瓦制药工业有限公司 度洛西汀hci多晶型物
US20100280093A1 (en) 2006-07-03 2010-11-04 Ranbaxy Laboratories Limited Process for the preparation enantiomerically pure salts of n-methyl-3-(1-naphthaleneoxy)-3-(2-thienyl)propanamine
CZ300116B6 (cs) * 2006-12-05 2009-02-11 Zentiva, A. S. Zpusob cištení hydrochloridu (S)-N-methyl-3-(1-naftyloxy)-3-(2-thienyl)propylaminu
WO2008077645A1 (en) 2006-12-22 2008-07-03 Synthon B.V. Process for making duloxetine and related compounds
HU227730B1 (en) 2006-12-22 2012-01-30 Richter Gedeon Nyrt Process for the preparation of duloxetine and for their the intermediates
US8269023B2 (en) 2007-03-05 2012-09-18 Lupin Ltd. Process for preparation of duloxetine hydrochloride
WO2009019719A2 (en) * 2007-08-09 2009-02-12 Ind-Swift Laboratories Limited Process for the preparation of 3-aryloxy-3-arylpropanamines
WO2009130708A2 (en) * 2008-04-22 2009-10-29 Shodhana Laboratories Limited Preparation of duloxetine and its salts
WO2010025287A2 (en) 2008-08-27 2010-03-04 Codexis, Inc. Ketoreductase polypeptides for the production of 3-aryl-3-hydroxypropanamine from a 3-aryl-3-ketopropanamine
WO2010025238A2 (en) 2008-08-27 2010-03-04 Codexis, Inc. Ketoreductase polypeptides for the production of a 3-aryl-3-hydroxypropanamine from a 3-aryl-3-ketopropanamine
WO2011033366A2 (en) 2009-09-16 2011-03-24 Jubilant Life Sciences Limited Process for the preparation of duloxetine hydrochloride and its precursors
CN103360365A (zh) * 2012-04-06 2013-10-23 李晓红 一种抗抑郁症药物原料药盐酸度洛西汀的制备新工艺
CN104230882B (zh) * 2014-08-29 2017-03-08 宁波美诺华药业股份有限公司 一种度洛西汀盐酸盐杂质的制备方法
CN104829587B (zh) * 2015-05-08 2017-07-21 上海万巷制药有限公司 盐酸度洛西汀的制备
CN107382958B (zh) * 2017-07-05 2021-11-09 浙江华海药业股份有限公司 一种度洛西汀中间体的结晶方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH578532A5 (de) * 1971-08-03 1976-08-13 Cassella Farbwerke Mainkur Ag
CA1181430A (en) 1980-11-14 1985-01-22 Bennie J. Foster (-) - n-methyl-3-(2-methylphenox)-3-phenylpropylamine, antidepressant
US4777291A (en) * 1985-02-27 1988-10-11 Eli Lilly And Company Racemization process
JPS62286959A (ja) * 1986-06-05 1987-12-12 Seitetsu Kagaku Co Ltd 光学活性シアノカルニチン塩の製造方法
US4956388A (en) * 1986-12-22 1990-09-11 Eli Lilly And Company 3-aryloxy-3-substituted propanamines
KR880007433A (ko) * 1986-12-22 1988-08-27 메리 앤 터커 3-아릴옥시-3-치환된 프로판아민
IL98108A0 (en) * 1990-05-17 1992-06-21 Lilly Co Eli Chiral synthesis of 1-aryl-3-aminopropan-1-ols
JPH09176157A (ja) * 1992-12-09 1997-07-08 Takeda Chem Ind Ltd 光学活性アミノクマラン誘導体
US5362886A (en) * 1993-10-12 1994-11-08 Eli Lilly And Company Asymmetric synthesis
US6458955B1 (en) 1994-12-16 2002-10-01 Uop Llc Process for preparation of pharmaceutically desired enantiomers
US6162949A (en) 1994-12-16 2000-12-19 Uop Llc Process for preparation of the pharmaceutically desired (S)-oxetine enantiomers
EP0792649A1 (de) * 1996-02-29 1997-09-03 Eli Lilly And Company Behandlung von Schlafstörungen
EA004539B1 (ru) * 1998-05-22 2004-06-24 Эли Лилли Энд Компани Комбинационная терапия для лечения резистентной депрессии
JP2002529499A (ja) 1998-11-13 2002-09-10 イーライ・リリー・アンド・カンパニー 痛みの治療方法
EP1171417B1 (de) * 1999-04-09 2005-11-09 Eli Lilly And Company Verfahren zur herstellung von 3-aryloxy-3-arylpropylamine und deren zwischenprodukte
US6677485B2 (en) * 1999-12-17 2004-01-13 Ranbaxy Laboratories Limited Process for the preparation of fluoxetine hydrochloride
EP1478641A1 (de) 2002-01-24 2004-11-24 Eli Lilly And Company Verfahren zur herstellung eines für die asymmetrische synthese von duloxetin geeigneten zwischenprodukts

Also Published As

Publication number Publication date
KR20050089839A (ko) 2005-09-08
DE60311599T2 (de) 2007-10-25
EP1690861B1 (de) 2012-09-12
AU2010200142A1 (en) 2010-02-04
AU2010200142B2 (en) 2012-04-12
CA2510750A1 (en) 2004-07-08
JP5259048B2 (ja) 2013-08-07
HRP20050657A2 (en) 2005-10-31
CN1747947A (zh) 2006-03-15
DE60311599D1 (de) 2007-03-22
MXPA05006659A (es) 2006-02-22
EP1690861A3 (de) 2006-09-06
CN100579975C (zh) 2010-01-13
WO2004056795A1 (en) 2004-07-08
RU2351594C2 (ru) 2009-04-10
PL377380A1 (pl) 2006-02-06
IL169232A (en) 2010-02-17
IS7915A (is) 2005-06-24
NZ540881A (en) 2008-09-26
MA27706A1 (fr) 2006-01-02
EP1587801A1 (de) 2005-10-26
TNSN05167A1 (en) 2007-05-14
CN101125848A (zh) 2008-02-20
EP1690861A2 (de) 2006-08-16
ES2279971T3 (es) 2007-09-01
NZ569874A (en) 2009-11-27
US7645890B2 (en) 2010-01-12
JP2006514030A (ja) 2006-04-27
AU2003292396A1 (en) 2004-07-14
BR0316902A (pt) 2005-10-25
ZA200505656B (en) 2006-04-26
WO2004056795A8 (en) 2005-08-11
AU2003292396B2 (en) 2010-05-20
PT1587801E (pt) 2007-04-30
KR100926723B1 (ko) 2009-11-16
US20060205956A1 (en) 2006-09-14
EP1587801B1 (de) 2007-01-31
CN101125848B (zh) 2012-09-12
GB0229583D0 (en) 2003-01-22
RU2005122662A (ru) 2006-01-20

Similar Documents

Publication Publication Date Title
ATE353081T1 (de) Verfahren zur herstellung von duloxetin und deren verwendeten zwischenprodukten
ATE494274T1 (de) Verfahren zum herstellen von 2-dihalogenacyl-3- amino-acryls ureestern und 3-dihalogenmethyl- pyrazol-4-carbons ureestern
BR0011445A (pt) Processo para a produção de tiazolidina
DE69830507D1 (de) Verfahren zur herstellung organischer boronsäurederivate mit hilfe von diboronsäure
ATE157647T1 (de) Verfahren zur herstellung von alpha- ketoamidderivaten
ATE477227T1 (de) Verfahren zur herstellung eines trans-4-amino-1- cyclohexancarbonsäurederivats
EP1247791A4 (de) Verfahren zur herstellung von perfluoroalkadienen
ATE359272T1 (de) Verfahren zur herstellung von 3-hydroxy-n-1,6-
ATE457972T1 (de) Verfahren zur herstellung von 7-amino-syn-3,5- dihydroxyheptansäurederivaten und zwischenverbindungen diesesverfahrens und deren herestellung
ATE310735T1 (de) Verfahren zur herstellung von spirocyclischen tetronsäurederivaten
DE60233256D1 (de) Verfahren zur herstellung von diphosphinverbindungen und zwischenprodukte für das verfahren
ATE334972T1 (de) Verfahren für die herstellung von 4(5)-amino-5(4)-carboxamidoimidazolen und deren zwischenprodukte
ATE384067T1 (de) Verfahren zur herstellung von 3-cephemderivaten
EP1211239A4 (de) Verfahren zur herstellung von 2,3-dihydroazepin-derivaten
ATE459617T1 (de) Verfahren zur herstellung von pyridinmethylsulphinylverbindungen
EP1229031A4 (de) Verfahren für die herstellung von 3,4-methylendioxy-mandelsäure
ATE478837T1 (de) Verfahren zur herstellung von benzylaminderivaten
ATE387421T1 (de) Verfahren zur herstellung von michael-addukten
ATE489385T1 (de) Verfahren zur herstellung von imidazopyridinen
ATE249434T1 (de) Ein verfahren zur herstellung von pyrrolidinon- derivaten
ATE256099T1 (de) Verfahren zur herstellung einer kristallsuspensionhenonen
ATE131483T1 (de) Verfahren zur herstellung von penemen
ATE260883T1 (de) Verfahren zur herstellung von atropasäureethylester
DE69909646T2 (de) Derivate der aminoacryl-säure und ein verfahren zur herstellung derselben
DE60028998D1 (de) Verfahren zur herstellung einer benzylamin-verbindung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties